Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R

Slides:

Advertisements

Similar presentations

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Advertisements

Poor growth in an infant with cystic fibrosis due to an antenatal perforation and incomplete bowel obstruction Isobel Brookes, Maya Desai, Gillian Duthie,

Donald R. VanDevanter, David J. Pasta, Michael W. Konstan

Treatment compliance in children and adults with Cystic Fibrosis

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis Cori Daines, Donald VanDeVanter,

Zhumin Zhang, Suzanne M. Shoff, HuiChuan J. Lai

Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort Margaret Rosenfeld, Julia Emerson, Sharon McNamara,

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

Scott D. Sagel, Marci K. Sontag, Meg M

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint D.R. VanDevanter, A. Yegin, W.J. Morgan,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

The ease of breathing test tracks clinical changes in cystic fibrosis

Pulmonary exacerbations in CF patients with early lung disease

Controlled clinical trials in cystic fibrosis — are we doing better?

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial S.K. Kabra, R. Pawaiya, Rakesh Lodha,

Nutritional status is associated with health-related quality of life in children with cystic fibrosis aged 9–19years Suzanne M. Shoff, Audrey Tluczek,

Amyloidosis in cystic fibrosis: A case series

A.H. Gifford Journal of Cystic Fibrosis

Inhalation solutions — Which ones may be mixed

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

Association between practice patterns and body mass index percentile in infants and young children with cystic fibrosis Raj Padman, Lloyd N. Werk, Gabriela.

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Depression and anxiety in adolescents and adults with cystic fibrosis in the UK: A cross- sectional study Alistair J.A. Duff, Janice Abbott, Carolyn Cowperthwaite,

Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J

Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis Christopher R. Sudfeld, Elliott C. Dasenbrook, William.

Cytokine gene polymorphisms and severity of CF lung disease

Nasal polyposis in lung transplant recipients with cystic fibrosis

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint M.W. Konstan, J.S. Wagener, A. Yegin, S.J.

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Higher risk of hospitalization among females with cystic fibrosis

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

A new method of sweat testing: the CF Quantum®sweat test

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis Cori Daines, Donald VanDeVanter,

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

CFTR modulators and pregnancy: Our work has only just begun

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Beta-lactam allergy in adults with cystic fibrosis

Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin,

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Cystic fibrosis and pregnancy in the modern era: A case control study

Respiratory physicians and clinic coordinators' attitudes to population-based cystic fibrosis carrier screening Fiona Cunningham, Sharon Lewis, Lisette.

Presentation transcript:

BMI fails to identify poor nutritional status in stunted children with CF Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R. VanDevanter, Wayne J. Morgan Journal of Cystic Fibrosis Volume 16, Issue 1, Pages 158-160 (January 2017) DOI: 10.1016/j.jcf.2016.11.005 Copyright © 2016 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Left Panels, entire cohort; Right Panels, lowest 10th WFA and HFA percentiles. (A) WFA and HFA percentiles among CF Children with BMI ≥50th percentile. (B) WFA and HFA percentiles among CF Children with BMI between 25th and <50th percentiles. (C) WFA and HFA percentiles among CF Children with BMI <25th percentile. Journal of Cystic Fibrosis 2017 16, 158-160DOI: (10.1016/j.jcf.2016.11.005) Copyright © 2016 European Cystic Fibrosis Society. Terms and Conditions